Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer

Murphy, Gerald P.; Troychak, M.J.; Cobb, Oliver E.; Bowes, Victoria; Kenny, Richard J.; Barren, Robert J.; Kenny, Gerald M.; Ragde, Haakon; Holmes, Eric H.; Wolfert, Robert L.

doi:10.1002/(sici)1097-0045(19971001)33:2<141::aid-pros8>3.0.co;2-n

Cited by 23 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were followed before, during, and after treatment with periodic PSA (Tandem-E PSA kit, Hybritech Incorporated, San Diego, CA), free PSA (Tandem-R PSA kit, Hybritech Incorporated), PSMA (inhouse Western blot assay), complete blood counts, CHEM-22, bone alkaline phosphatase (Tandem-R Ostase kit, Hybritech Incorporated), inital chest X-ray, bone scans, and ProstaScint scans [13,14]. All testing was conducted on an outpatient basis at Northwest Hospital.…”

Section: Clinical Monitoringmentioning

confidence: 99%

Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment

et al. 1999

View full text Add to dashboard Cite

BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA‐A2‐specific prostate‐specific membrane antigen (PSMA) peptides (PSM‐P1 and ‐P2). This report describes the evaluation of 37 subjects admitted with presumed local recurrence of prostate cancer after primary treatment failure. METHODS All subjects received six infusions of DC pulsed with PSM‐P1 and ‐P2 at 6‐week intervals. Clinical monitoring was conducted pre‐, during, and post‐phase II study. Data included: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, ProstaScint® scan, and chest X‐ray, as well as other assays to monitor cellular and humoral immune responses. RESULTS One complete and 10 partial responders were identified from this group based on National Prostate Cancer Project criteria, or on a 50% reduction of prostate‐specific antigen (PSA), or on a significant resolution in lesions (biopsy‐proven when possible) on ProstaScint® scan. CONCLUSIONS About 30% of study participants in this group showed a positive response at the conclusion of the trial. This study suggests that DC‐based cancer vaccines may provide an alternative therapy for prostate cancer patients whose primary treatment failed. Prostate 39:54–59, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

Section: Clinical Monitoringmentioning

confidence: 99%

Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Patients were monitored throughout the course of their six infusions with periodic prostate-specific antigen (PSA; Tandem-E PSA kit, Hybritech Incorporated, San Diego, CA), free-PSA (Tandem-R PSA kit, Hybritech Incorporated), PSMA (in-house Western blot assay), complete blood counts, CHEM-22, bone alkaline phosphatase (Tandem-R Ostase kit, Hybritech Incorporated), chest X-rays, bone scans, and Prosta-Scint (Cytogen Corporation, Princeton, NJ) scans [8,9]. Patients were evaluated for clinical and biochemical adverse events.…”

Section: Clinical Monitoringmentioning

confidence: 99%

GM‐CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

et al. 1999

View full text Add to dashboard Cite

BACKGROUND. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine [sargramostim], Immunex Corp., Seattle, WA) was administered to a subgroup of 44 patients in a phase II clinical trial for prostate cancer using DC pulsed with HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides. Our purpose was to determine if GM-CSF caused any enhancement of patients' immune responses, including enhancement of clinical response to the DC-peptide treatment. This report compares the clinical responses to DC-peptide infusions with and without systemic GM-CSF treatment. METHODS. GM-CSF was administered by subcutaneous injection at a dose of 75 g/m 2 /day for 7 days with each of six infusion cycles. Prefilled syringes were supplied to the patients for self-administration. RESULTS. One complete and 8 partial responders were identified among 44 patients who received GM-CSF, as compared to 2 complete and 17 partial responders among 51 patients who did not receive GM-CSF. For patients who received GM-CSF and were tested by delayedtype hypersensitivity (DTH) skin test, 3 cases of improved immune response were identified, compared to 5 cases of improvement in patients who did not receive GM-CSF. The main GM-CSF side effects reported were local reactions at the site of injection, fatigue, pain, and fever. Most reported side effects were of mild severity, with some cases of moderate severity leading to discontinuation of GM-CSF. CONCLUSIONS. Our results suggest GM-CSF as employed in this trial did not detectably enhance clinical response to DC-peptide infusions, or significantly enhance the measured immune response.

show abstract

“…It has been shown that when the PSMA -/PSA + profile decreased in normal prostates, benign prostatic tissue, and primary prostate cancers, the PSMA + /PSAlevel increased from normal to prostate tumor tissues. Generally, researchers support the idea that the amount of PSMA and/or PSA in healthy men is low in the blood and it increases either with age or because of inflammation of prostate gland (prostatitis) or prostatecancer [16,17,21,22,23] To decrease the side effects of any prostate therapy, it is crucial to develop a good screening pattern for preventing the disease. Finding a tumor at an early stage may be easier to treat before it will cause serious symptoms.…”

Section: Discussionmentioning

confidence: 99%

How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations?

Maria¹,

Apostolou²,

Chatziioannou³

et al. 2014

J Can Res Ther

View full text Add to dashboard Cite

show abstract

Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer

Cited by 23 publications

References 17 publications

Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment

Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment

GM‐CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations?

Contact Info

Product

Resources

About